The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 524 KB) and Technical Notes (PDF, 762 KB) pages.


Download and Print: Download Printer-friendly PDF Download data

Table 19.29

All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis
All Races, Both Sexes, 2005-2011
Site All Ages Ages 0-19 Ages 20-64 Ages 65+
Count Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval
Low High Low High Low High Low High
Lymphoid Neoplasm 171,838 69.0 68.7 69.3 89.5 88.8 90.2 76.6 76.2 76.9 58.4 57.9 59.0
1 Hodgkin Lymphoma 14,979 85.9 85.2 86.6 97.0 96.1 97.8 89.9 89.1 90.5 53.6 50.5 56.5
2 Non-Hodgkin lymphoma 152,478 67.8 67.5 68.2 87.4 86.5 88.2 74.8 74.4 75.2 59.2 58.6 59.7
2(a) Non-Hodgkin lymphoma, B-cell 140,008 68.3 67.9 68.6 88.4 87.4 89.3 75.7 75.3 76.1 59.8 59.2 60.4
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell 7,457 68.6 67.3 69.7 88.2 87.0 89.2 37.6 35.2 40.0 16.0 12.3 20.1
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell 126,080 68.2 67.9 68.6 88.8 86.6 90.6 77.1 76.6 77.5 59.9 59.4 60.5
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma 30,161 77.6 76.9 78.4 - - - 86.0 85.1 86.8 72.0 70.8 73.1
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma 26,520 80.7 79.9 81.5 - - - 88.8 87.9 89.7 75.3 74.1 76.5
2(a) 2.1.2. Prolymphocytic leukemia, B-cell 105 43.2 30.5 55.3 - - - 57.0 36.0 73.5 35.4 20.0 51.1
2(a) 2.1.3. Mantle-cell lymphoma 3,536 55.8 53.5 58.0 - - - 67.7 64.7 70.6 45.9 42.6 49.1
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglubulinemia 2,736 80.1 77.4 82.5 - - - 87.6 84.5 90.1 75.5 71.6 78.9
2(a) 2.2.1. Lymphoplasmacytic lymphoma 1,237 74.9 70.7 78.6 - - - 82.6 77.3 86.8 70.2 64.3 75.4
2(a) 2.2.2. Waldenstrom macroglubulinemia 1,499 84.2 80.6 87.1 - - - 91.0 87.2 93.7 79.7 74.4 84.1
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL) 33,046 61.2 60.6 61.9 87.0 83.3 90.0 70.7 69.8 71.5 51.6 50.5 52.6
2(a) 2.3.1. DLBCL, NOSc 32,657 61.1 60.4 61.8 88.1 84.4 91.0 70.5 69.7 71.4 51.6 50.5 52.7
2(a) 2.3.2. Intravascular large B-cell lymphoma 42 51.0 32.9 66.5 - - - - - - - - -
2(a) 2.3.3. Primary effusion lymphoma 54 22.5 10.8 36.9 - - - 24.1 10.4 40.9 - - -
2(a) 2.3.4. Mediastinal large B-cell lymphoma 293 83.2 77.5 87.6 - - - 87.8 82.1 91.8 - - -
2(a) 2.4. Burkitt lymphoma/leukemia 2,198 59.1 56.8 61.3 88.7 85.3 91.3 56.3 53.3 59.1 33.0 27.2 38.9
2(a) 2.5. Marginal-zone lymphoma (MZL) 9,101 89.6 88.4 90.7 98.4 89.3 99.8 92.5 91.2 93.6 86.8 84.7 88.7
2(a) 2.5.1. Splenic MZL 787 83.9 79.1 87.7 - - - 85.4 79.7 89.6 82.4 74.3 88.1
2(a) 2.5.2. Extranodal MZL, MALTc type 5,450 94.0 92.4 95.3 97.5 83.5 99.6 95.5 94.1 96.7 92.4 89.3 94.6
2(a) 2.5.3. Nodal MZL 2,864 82.8 80.5 85.0 - - - 87.7 85.0 90.1 78.4 74.6 81.6
2(a) 2.6. Follicular lymphoma 17,933 86.4 85.5 87.1 94.6 79.2 98.7 90.9 90.1 91.6 80.2 78.6 81.8
2(a) 2.7. Hairy-cell leukemia 1,460 93.5 90.9 95.5 - - - 97.4 95.6 98.5 82.9 75.0 88.6
2(a) 2.8. Plasma cell neoplasms 29,416 46.4 45.6 47.2 - - - 59.5 58.4 60.6 36.1 35.0 37.2
2(a) 2.8.1. Plasmacytoma 1,837 66.6 63.5 69.5 - - - 78.3 74.8 81.4 51.0 45.6 56.1
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia 27,579 45.0 44.2 45.9 - - - 57.8 56.7 59.0 35.4 34.3 36.5
2(a) 2.9. Heavy chain disease 29 53.1 28.0 73.0 - - - - - - - - -
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOSc 6,471 69.1 67.4 70.7 92.6 82.9 96.9 76.4 74.2 78.4 64.1 61.6 66.4
2(b) Non-Hodgkin lymphoma, T-cell 10,425 64.0 62.9 65.1 84.2 81.9 86.3 67.5 66.1 68.9 50.4 48.0 52.8
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell 794 64.2 60.5 67.7 85.0 80.8 88.3 47.3 41.4 53.0 10.6 3.1 23.4
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell 9,567 64.2 62.9 65.4 83.9 80.9 86.4 68.9 67.5 70.4 51.3 48.8 53.7
2(b) 2.1. Mycosis fungoides/Sezary syndrome 2,422 89.2 86.9 91.1 94.7 76.6 98.9 92.2 90.0 94.0 82.2 76.3 86.7
2(b) 2.1.1. Mycosis fungoides 2,353 90.7 88.4 92.5 94.7 76.6 98.9 93.0 90.9 94.7 85.2 79.0 89.6
2(b) 2.1.2. Sezary syndrome 69 34.0 19.1 49.6 - - - 45.5 21.8 66.5 25.4 9.0 45.9
2(b) 2.2. Peripheral T-cell lymphoma 5,490 57.0 55.3 58.6 81.4 75.9 85.8 64.2 62.2 66.2 43.1 40.3 45.9
2(b) 2.2.1. Peripheral T-cell lymphoma, NOSc 1,866 37.9 35.2 40.7 60.2 43.6 73.2 44.9 41.2 48.6 28.3 24.2 32.6
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma 716 43.8 39.3 48.1 - - - 55.4 48.9 61.4 33.7 27.6 39.9
2(b) 2.2.3. Subcutaneous panniculitis- like T-cell lymphoma 81 72.6 56.6 83.5 - - - 72.4 52.0 85.2 - - -
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type 1,147 58.4 55.1 61.5 86.2 79.6 90.8 62.4 58.4 66.1 32.8 26.1 39.6
2(b) 2.2.5. Hepatosplenic T-cell lymphoma 49 27.3 14.8 41.3 - - - 33.0 17.6 49.4 - - -
2(b) 2.2.6. Enteropathy-type T-cell lymphoma 60 14.4 6.3 25.6 - - - 16.4 5.7 31.9 13.2 3.3 29.9
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOSc 1,060 82.8 79.1 85.9 - - - 87.3 83.3 90.4 75.3 67.7 81.4
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma 511 90.6 85.5 94.0 - - - 94.7 89.6 97.3 81.8 68.1 90.1
2(b) 2.3. Adult T-cell leukemia/lymphoma 958 58.4 54.6 62.0 84.7 80.7 88.0 37.5 31.4 43.6 16.3 8.1 27.0
2(b) 2.4. NKc/T-cell lymphoma, nasal-type/ agressive NKc-cell leukemia 428 43.1 37.6 48.6 - - - 42.7 36.5 48.8 40.6 27.2 53.6
2(b) 2.5. T-cell large granular lymphocytic leukemia 120 69.4 57.1 78.8 - - - 77.8 59.7 88.6 59.4 42.0 73.1
2(b) 2.6. Prolymphocytic leukemia, T-cell 149 13.5 6.9 22.3 - - - 14.0 5.4 26.8 13.0 4.5 26.1
2(b) 3. Non-Hodgkin lymphoma, NOSc , T-cell 64 38.7 26.2 51.0 - - - 54.2 36.4 68.9 - - -
2(c) Non-Hodgkin lymphoma, unknown lineage 2,045 58.7 56.2 61.1 84.7 81.3 87.6 55.1 50.9 59.0 43.2 38.7 47.5
2(c) 1. Precursor lymphoblastic leukemia/ lymphoma, unknown lineage 914 63.9 60.5 67.1 85.2 81.8 88.1 36.1 29.3 42.8 23.4 15.7 31.9
2(c) 2. Prolymphocytic leukemia, unknown lineage 54 50.0 33.5 64.4 - - - - - - 41.0 22.5 58.7
2(c) 3. Non-Hodgkin lymphoma, NOSc, unknown lineage 1,077 54.7 51.0 58.3 - - - 64.7 59.5 69.4 47.4 42.2 52.4
2(*) 1. Total precursor lymphoma/leukemiad 9,165 67.8 66.7 68.8 87.7 86.7 88.6 38.8 36.7 40.9 17.3 14.1 20.9
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma 85 64.4 50.1 75.6 - - - 71.4 55.0 82.7 50.5 25.1 71.3
4 Lymphoid neoplasm, NOSc 4,296 49.3 47.3 51.2 85.4 73.9 92.2 61.8 59.0 64.4 40.1 37.4 42.8

Footnotes:

a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.